VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
OMER
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
OMEROmeros Corporation
$14.55$1.1B
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
HomeStocksOMERFinancials

Omeros Corporation (OMER) Income Statement

19Y historyFree accessUpdated daily

The Q2 2026 revenue of $28.5 million marks a critical commercial inflection, but the 97.2% gross margin is almost entirely consumed by $13.8 million in R&D expenses, resulting in a near-breakeven operating margin of 0.3%.

Income StatementBalance SheetCash FlowRatios

OMER Income Statement

Annual statement

OMER Income Statement

Omeros Corporation (OMER) annual income statement — 19-year revenue, gross profit & net income history

AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09Dec'08Dec'07
Sales/Revenue74.36M000000111.81M29.87M64.83M41.62M13.51M539K1.6M6.02M4.52M2.1M1.44M1.17M1.92M
Revenue Growth %-------100%274.33%-53.93%55.77%208.07%2406.31%-66.31%-73.43%33.11%114.92%45.78%23.42%-39.16%-
Cost of Goods Sold33.06M00001.39M1.62M2.65M512K1.08M1.41M1.04M26.73M18.33M18.46K00000
COGS % of Revenue-------2.37%1.71%1.66%3.39%7.71%4958.81%1145.38%0.31%-----
Gross Profit41.3M0000-1.39M-1.62M109.15M29.36M63.75M40.2M12.47M-26.19M-16.73M6M4.52M2.1M1.44M1.17M1.92M
Gross Margin %55.54%------97.63%98.29%98.34%96.61%92.29%-4858.81%-1045.38%99.69%100%100%100%100%100%
Gross Profit Growth %----100%14.23%-101.48%271.81%-53.95%58.56%222.47%147.61%-56.58%-378.6%32.7%114.92%45.78%23.42%-39.16%-
Operating Expenses113.83M122.8M169.26M164.53M163.39M172.23M155.3M172.53M141.58M107.64M94.48M83.71M70.55M52.12M42.91M31.93M32.21M22.2M25.7M26.32M
OpEx % of Revenue-------154.32%474.01%166.05%227.02%619.63%13088.5%3257.25%712.5%705.88%1530.21%1537.53%2196.15%1368.69%
Selling, General & Admin51.41M41.5M49.73M49.66M50.67M53.46M47.69M62.84M51.72M52.04M43.78M35.33M22.6M15.82M10.98M8.22M8.75M5.27M7.84M10.4M
SG&A % of Revenue-------56.2%173.16%80.28%105.2%261.51%4193.14%988.69%182.41%181.61%415.49%365.17%670.51%540.72%
Research & Development62.42M81.3M119.52M114.87M112.72M118.78M107.61M109.7M89.86M55.6M50.7M48.38M47.95M36.3M31.92M23.72M23.46M16.93M17.85M15.92M
R&D % of Revenue-------98.11%300.86%85.77%121.82%358.12%8895.36%2268.56%530.09%524.27%1114.73%1172.37%1525.64%827.98%
Other Operating Expenses0000000000945K0-207K574K130K0000-125K
Operating Income-41.93M-122.8M-169.26M-164.53M-163.39M-173.62M-156.92M-63.38M-112.22M-43.9M-54.28M-71.24M-70.01M-50.52M-36.88M-27.41M-30.11M-20.76M-24.52M-24.4M
Operating Margin %-56.39%-------56.69%-375.73%-67.71%-130.42%-527.34%-12988.5%-3157.25%-612.5%-605.88%-1430.21%-1437.53%-2096.15%-1268.69%
Operating Income Growth %-27.45%-2.87%-0.7%5.89%-10.64%-147.57%43.52%-155.66%19.13%23.81%-1.76%-38.59%-36.96%-34.57%8.96%-45.03%15.36%-0.52%-
EBITDA-41.1M-121.83M-168.31M-163.61M-162.44M-172.23M-155.3M-61.59M-111.26M-43.34M-53.98M-71.03M-69.68M-50.21M-36.56M-26.98M-29.63M-20.31M-24.09M-24.02M
EBITDA Margin %-55.28%-------55.09%-372.51%-66.86%-129.7%-525.79%-12928.01%-3138.38%-607.19%-596.26%-1407.79%-1406.3%-2059.06%-1249.19%
EBITDA Growth %67.98%27.61%-2.87%-0.72%5.69%-10.9%-152.15%44.64%-156.69%19.7%24.01%-1.93%-38.77%-37.33%-35.55%8.97%-45.93%15.71%-0.29%-
D&A (Non-Cash Add-back)826K964K950K920K952K1.39M1.62M1.79M962K551K300K209K326K302K320K435K472K451K434K375K
EBIT95.8M-2.8M-157.95M-144.08M-159.33M-171.88M-169.64M-61.83M-123.43M-42.45M-58.93M-71.52M-70.2M-37.43M-36.72M-26.66M-27.72M-20.76M-24.52M-22.94M
Net Interest Income-25.09M5.06M-13.37M-14.5M-18.64M-19.65M-26.1M-22.66M-16.25M-11.03M-7.82M-3.57M-3.47M-2.37M-1.73M-1.88M-1.53M-2.2M-335K-151K
Interest Income3.34M5.06M11.3M16.34M4.06M17.93K654K0000000000000
Interest Expense28.43M024.68M30.84M22.7M19.67M26.75M22.66M16.25M11.03M7.82M3.57M3.47M2.37M1.73M1.88M1.53M2.2M335K151K
Other Income/Expense118.02M120M-13.37M-10.39M-18.64M-17.93M-39.47M-21.1M-27.46M-9.59M-12.47M-3.86M-3.67M10.72M-1.56M-1.14M855K-331K698K1.31M
Pretax Income76.09M-2.8M-182.63M-174.92M-182.03M-191.55M-196.39M-84.49M-139.69M-53.48M-66.75M-75.1M-73.67M-39.8M-38.44M-26.66M-27.72M-18.89M-23.83M-23.09M
Pretax Margin %102.34%-------75.57%-467.68%-82.5%-160.38%-555.9%-13668.46%-2487.25%-638.39%-589.35%-1316.67%-1307.96%-2036.5%-1200.78%
Income Tax2.14M2.01M0000-23.26M0-12.93M0000001.14M-855K331K026K
Effective Tax Rate %2.82%-71.96%0%0%0%0%11.84%0%9.26%0%0%0%0%0%0%-4.26%3.08%-1.75%0%-0.11%
Net Income98.39M-3.35M-156.81M-117.81M47.42M-111.41M-138.06M-84.49M-126.76M-53.48M-66.75M-75.1M-73.67M-39.8M-38.44M-28.55M-29.25M-21.09M-23.83M-23.09M
Net Margin %132.32%-------75.57%-424.39%-82.5%-160.38%-555.9%-13668.46%-2487.25%-638.39%-630.99%-1389.6%-1460.46%-2036.5%-1200.78%
Net Income Growth %181.2%97.86%-33.11%-348.46%142.56%19.3%-63.41%33.35%-137.01%19.87%11.12%-1.93%-85.13%-3.52%-34.67%2.41%-38.7%11.49%-3.19%-
Net Income (Continuing)73.95M-4.81M-182.63M-174.92M-182.03M-191.55M-173.13M-84.49M-126.76M-53.48M-66.75M-75.1M-73.67M-39.8M-38.44M-28.55M-29.25M-21.09M-23.83M-23.09M
Discontinued Operations4M1.46M25.81M57.11M229.45M80.13M35.07M0000000000000
Minority Interest00000000000000000000
EPS (Diluted)1.35-0.05-2.70-1.880.46-1.79-2.41-2.16-2.61-1.17-1.65-2.00-2.22-1.39-1.59-1.29-1.37-2.92-2.22-1.62
EPS Growth %169.31%98.05%-43.62%-508.7%125.7%25.73%-11.57%17.24%-123.08%29.09%17.5%9.91%-59.71%12.58%-23.26%5.84%53.08%-31.53%-37.04%-
EPS (Basic)--0.05-2.70-1.880.46-1.79-2.41-2.16-2.61-1.17-1.65-2.00-2.22-1.39-1.59-1.29-1.37-2.92-2.22-1.62
Diluted Shares Outstanding72.98M63.51M58.17M62.74M62.74M62.34M57.18M49.52M48.58M45.54M40.45M37.56M33.23M28.56M24.16M22.21M21.42M7.22M10.75M14.27M
Basic Shares Outstanding72.98M63.51M58.17M62.74M62.74M62.34M57.18M49.52M48.58M45.54M40.45M37.56M33.23M28.56M24.16M22.21M21.42M7.22M10.75M14.27M
Dividend Payout Ratio--------------------

Key Metrics

Growth RegimeAccelerating
ProfitabilityStrained
Balance SheetVulnerable
Cash FlowBurning
Top Statement Risk

Critical liquidity and regulatory risk

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q2)

Revenue Emergence from Royalty Base

Omeros's revenue trajectory has shifted from zero to a meaningful $28.5 million in Q2 2026, driven by the initial commercial launch of YARTEMLEA, marking a critical transition from a pure R&D entity to a commercial-stage biotech.

The sudden appearance of $28.5 million in revenue in Q2 2026, after multiple quarters of zero reported revenue, represents a fundamental inflection in the company's income statement. This revenue is likely tied to the commercial launch of YARTEMLEA, suggesting the company is now generating sales from a marketed product rather than relying solely on milestone payments or royalties. The durability of this revenue stream is the key question, as the company's prior revenue history was inconsistent and often zero.

Royalty-Like Gross Margins Mask Operating Losses

The reported 97.2% gross margin in Q2 2026 is exceptionally high, suggesting a royalty or high-margin specialty product structure, but this is completely offset by heavy R&D and SG&A spending, resulting in a near-breakeven operating margin.

The 97.2% gross margin is characteristic of a royalty stream or a product with minimal cost of goods sold, which aligns with the company's transition to a royalty-based model for Omidria. However, this structural advantage is negated by the company's high fixed-cost base, with R&D and SG&A totaling $27.7 million in Q2 2026, nearly matching the gross profit. This indicates that while the product itself is highly profitable, the corporate overhead required to support it and advance the pipeline remains substantial.

Operating Leverage Unproven at Scale

Despite achieving a positive operating income of $74,000 in Q2 2026, the company's operating leverage remains unproven, as the result appears driven by a single quarter's revenue spike rather than a sustainable reduction in the cost base.

The shift from a $17.4 million operating loss in Q1 2026 to a marginal profit in Q2 2026 is a positive signal, but it is almost entirely attributable to the $18.6 million sequential increase in revenue. The combined R&D and SG&A expenses actually increased slightly quarter-over-quarter, suggesting no meaningful improvement in overhead efficiency. True operating leverage would require demonstrating that incremental revenue can flow to the bottom line without a proportional increase in the cost structure, which has not yet been established.

R&D Dominates Cost Structure

Research and development expenses of $13.8 million in Q2 2026 represent the single largest cost line, consuming nearly half of gross profit and underscoring the company's continued heavy investment in its clinical pipeline despite recent commercial progress.

The cost structure is dominated by R&D, which at $13.8 million in Q2 2026 is roughly equal to SG&A at $13.9 million. This balance suggests the company is simultaneously funding late-stage clinical programs and building commercial capabilities. The high R&D spend is a strategic necessity for a biotech with multiple pipeline candidates, but it also means that profitability is highly sensitive to the pace of clinical trial execution and regulatory milestones.

Q2 2026: First Commercial Revenue Quarter

The second quarter of 2026 represents the most significant operational inflection in Omeros's recent history, as it marks the first quarter with substantial recognized revenue, fundamentally altering the company's income statement profile from a pure cash-burn entity.

Prior to Q2 2026, the company's income statement was characterized by zero or minimal revenue and consistent operating losses funded by cash reserves and financing. The $28.5 million in revenue in Q2 2026 changes the narrative, providing a proof-of-concept for commercial execution. This inflection point is critical because it demonstrates the company's ability to generate top-line sales, which is a prerequisite for any path to long-term profitability, though the sustainability of this initial launch quarter remains to be seen.

Sustainability of Launch Quarter in Question

The strong Q2 2026 results may represent an unsustainable launch spike, as the company's history of zero revenue quarters and a cash position of only $9.66 million suggests limited runway to support operations if the revenue ramp disappoints.

A skeptical view would focus on the fact that $28.5 million in revenue appeared suddenly after many quarters of zero, raising questions about the durability of this sales trajectory. The company's reported cash and equivalents of approximately $9.66 million is critically low, indicating that any shortfall in the expected revenue ramp could force an immediate and dilutive capital raise. Furthermore, the operating income of $74,000 is razor-thin and would quickly turn negative if R&D or SG&A spending increases or if revenue does not grow sequentially.

OMER — Frequently Asked Questions

Quick answers to the most common questions about buying OMER stock.

What was Omeros Corporation's (OMER) revenue in 2025?

For fiscal year 2025, Omeros Corporation (OMER) reported total revenue of $0.0M. This represents a 100.0% decline compared to $1.9M in 2007.

Is Omeros Corporation (OMER) profitable?

Omeros Corporation (OMER) reported a net loss of $3.4M for the fiscal year ending 2025.